Bioclinica acquires clinical trial AI firm

By The Science Advisory Board staff writers

January 6, 2021 -- Clinical trial management services firm Bioclinica has acquired Saliency, the developer of an artificial intelligence (AI)-based software that speeds medical image interpretation to help support pharmaceutical and medical device clients in clinical trials.

Saliency's platform uses proprietary algorithms to build and train AI models quickly from a small number of deidentified images. The models can be used to screen, redact, or interpret medical images to support numerous therapeutic areas.

The AI capability will be embedded into Bioclinica's current and future imaging products and services for research sponsors and clinical research organizations.

Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases.
Google's DeepMind makes a quantum leap in solving the protein folding problem
Artificial intelligence has made something of a breakthrough in the prediction of protein structures. The results came about as part of the 14th Critical...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter